Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
EGFR T790M
i
Other names:
EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
1956
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
EGFR mutation (196)
EGFR L858R (90)
EGFR exon 20 insertion (50)
EGFR wild-type (41)
EGFR L861Q (23)
EGFR C797S (22)
EGFR exon 21 mutation (20)
EGFR L858R + EGFR T790M (16)
EGFR exon 19 mutation (14)
EGFR A763_Y764insFQEA (13)
EGFR G719X (13)
EGFR S768I (12)
EGFR mutation + TP53 mutation (11)
EGFR C797S + EGFR T790M + EGFR L858R (9)
EGFR C797S + EGFR T790M + EGFR exon 19 deletion (9)
EGFR E746_A750del (8)
EGFR exon 20 mutation (8)
EGFRvIII mutation (8)
EGFR G719A (7)
EGFR G719S (7)
EGFR L747P (7)
EGFR exon 18 mutation (7)
EGFR T790M + EGFR C797S (6)
EGFR exon 19 deletion + EGFR L861Q (6)
EGFR mutation + BRAF V600E (6)
EGFR wild-type + ALK wild-type (6)
EGFR G719X + EGFR S768I (5)
EGFR K745_E746insIPVAIK (5)
EGFR G719C (4)
EGFR L861Q + EGFR G719X (4)
EGFR S492R (4)
EGFR mutation + KRAS mutation (4)
EGFR mutation + PIK3CA mutation (4)
EGFR D770 delinsGY (3)
EGFR D770_N771insSVD (3)
EGFR E709K (3)
EGFR E709_T710delinsD (3)
EGFR E746_S752delinsV (3)
EGFR G724S (3)
EGFR H773_V774insH (3)
EGFR L718Q (3)
EGFR L833V + EGFR H835L (3)
EGFR L858R + EGFR M766Q (3)
EGFR R521K (3)
EGFR T790M negative (3)
EGFR T854A (3)
EGFR exon 18-25 duplication (3)
EGFR exon 19 deletion + EGFR C797S (3)
EGFR exon 19 deletion + EGFR T790M + EGFR C797S (3)
EGFR mutation + CREBBP mutation (3)
HER-2 V777L + EGFR L858R (3)
EGFR A767_V769dup (2)
EGFR D761Y (2)
EGFR D770_N771insGT (2)
EGFR E114K (2)
EGFR G465R (2)
EGFR G63R (2)
EGFR G719A + EGFR G779C (2)
EGFR G719C + EGFR S768I (2)
EGFR G719S + EGFR L861Q (2)
EGFR G874S (2)
EGFR H1975 (2)
EGFR K708R (2)
EGFR L747-S752 del (2)
EGFR L747_A750delinsP (2)
EGFR L833F + EGFR L861Q (2)
EGFR L858R + EGFR A871G (2)
EGFR L858R + EGFR L718Q (2)
EGFR L858R + RBM10 Y36* (2)
EGFR L858R + TP53 mutation (2)
EGFR L860R (2)
EGFR L861R (2)
EGFR N771delinsKG (2)
EGFR P596L (2)
EGFR R165Q (2)
EGFR R222C (2)
EGFR S645C + EGFR L858R (2)
EGFR T790M + KRAS mutation (2)
EGFR T790M + PIK3CA H1047R (2)
EGFR V802I + KRAS mutation (2)
EGFR exon 19 duplication (2)
EGFR exon 19 insertion (2)
EGFR exon 20 insertion + EGFR T790M (2)
EGFR mutation + ATM mutation (2)
EGFR mutation + BRAF V600 (2)
EGFR mutation + CDKN2A mutation (2)
EGFR mutation + EGFR T790M (2)
EGFR mutation + MET mutation (2)
EGFR mutation + NRAS Q61K (2)
EGFR mutation + PTEN mutation (2)
EGFR mutation + TP53 mutation + ARID1A mutation (2)
EGFR mutation + TP53 mutation + BRCA1 mutation (2)
EGFR mutation + TP53 mutation + NF1 mutation (2)
EGFR mutation + TP53 mutation + PTEN mutation (2)
EGFR mutation + TP53 mutation + RB1 mutation (2)
EGFR T790L (2)
EGFR delE709_T710insD (2)
KRAS mutation + EGFR wild-type (2)
MET exon 14 mutation + EGFR exon 20 insertion (2)
ALK L1152R + EGFR mutation (1)
ALK rearrangement + ALK T1151M + ALK L1198F + EGFR A839V (1)
ALK rearrangement + EGFR D761N + KRAS V14I (1)
ALK rearrangement + TP53 R175H + EGFR A839V + PI3KCA mutation (1)
BRAF mutation + EGFR mutation (1)
CDK4 mutation + EGFR mutation (1)
DDR + EGFR mutation (1)
EGFR 181946 C>T (1)
EGFR A289V (1)
EGFR A750P (1)
EGFR A763V (1)
EGFR A767_V769dupASV (1)
EGFR A767dupASV (1)
EGFR A859T (1)
EGFR C796S (1)
EGFR C796S + EGFR V802I (1)
EGFR C797S + EGFR C796S (1)
EGFR C797S + EGFR exon 20 insertion (1)
EGFR D770_N771insGL (1)
EGFR D770_N771insGT + EGFR V774_C775insHV (1)
EGFR E690K (1)
EGFR E709A + EGFR G719C (1)
EGFR E709G (1)
EGFR E709Q (1)
EGFR E746 (1)
EGFR E746G (1)
EGFR E746_T751delinsl (1)
EGFR E758D (1)
EGFR E884K (1)
EGFR G2607A (1)
EGFR G709T (1)
EGFR G719A + EGFR I706T (1)
EGFR G719A + EGFR L833V (1)
EGFR G719A + EGFR R776C (1)
EGFR G719A + EGFR S768I (1)
EGFR G719A + EGFR T790M (1)
EGFR G719C + EGFR E709V (1)
EGFR G719D (1)
EGFR G719S + EGFR S768I (1)
EGFR G719X + EGFR E709F (1)
EGFR G719X + EGFR L861Q + EGFR S768I (1)
EGFR G719X + TP53 mutation (1)
EGFR G724S + EGFR R776H (1)
EGFR G735R (1)
EGFR G796S (1)
EGFR G836S (1)
EGFR H773L + EGFR V774M (1)
EGFR H773_V774insNPH (1)
EGFR H773delinsNPY (1)
EGFR H773delinsYNPY (1)
EGFR H835L (1)
EGFR I744_K745insKIPVAI (1)
EGFR K467T (1)
EGFR K757R (1)
EGFR L718V + TP53 V727M + EGFR L858R (1)
EGFR L746_T70delinsS (1)
EGFR L746_T750del (1)
EGFR L747S (1)
EGFR L747_A750>P (1)
EGFR L747_P753delinsS (1)
EGFR L747_T751delinsP (1)
EGFR L747_T751delinsS (1)
EGFR L747_T753delinsS (1)
EGFR L833V (1)
EGFR L8585R + EGFR T790M + RBM10 G840fs*7 (1)
EGFR L858R + ALK R1275Q (1)
EGFR L858R + ALK rearrangement (1)
EGFR L858R + EGFR C797S (1)
EGFR L858R + EGFR D761Y (1)
EGFR L858R + EGFR E709G (1)
EGFR L858R + EGFR E709X (1)
EGFR L858R + EGFR E709X + CTNNB1 mutation (1)
EGFR L858R + EGFR E884K (1)
EGFR L858R + EGFR L747V (1)
EGFR L858R + EGFR R776H (1)
EGFR L858R + EGFR S765I (1)
EGFR L858R + EGFR S768I (1)
EGFR L858R + EGFR T854A (1)
EGFR L858R + EGFR V843I (1)
EGFR L858R + EGFR exon 21 deletion (1)
EGFR L858R + FGF3 mutation (1)
EGFR L858R + IDH1 R132C (1)
EGFR L858R + PIK3CA H1047R + PIK3CA E545K (1)
EGFR L858R + RBM10 2167-1 G>T (1)
EGFR L858R + RBM10 Q255* (1)
EGFR L858R + RBM10 Q595* (1)
EGFR L858R + TP53 R273C + HER-2 S442L (1)
EGFR L858R + TP53 wild-type (1)
EGFR L861P (1)
EGFR L861Q + EGFR exon 20 insertion (1)
EGFR L861Q + TP53 mutation (1)
EGFR L861Q + TP53 mutation + RB1 mutation (1)
EGFR L861X (1)
EGFR M277E (1)
EGFR M766Q (1)
EGFR M766_A767insASV (1)
EGFR N771_P772insH (1)
EGFR N771_P772insVal (1)
EGFR P546S (1)
EGFR P753S (1)
EGFR P772_H773insYNP (1)
EGFR P772_H773insYNP + EGFR H773Y (1)
EGFR P772_V774insPHV (1)
EGFR Q787Q (1)
EGFR R1052K (1)
EGFR R451C (1)
EGFR R776C + EGFR L861Q (1)
EGFR R776H (1)
EGFR R776H + EGFR C797S (1)
EGFR R776H + EGFR L861Q (1)
EGFR S464L (1)
EGFR S720I (1)
EGFR S752_I759del (1)
EGFR S768I + TP53 mutation (1)
EGFR S768_D770dup (1)
EGFR S768_D770dupSVD (1)
EGFR S768dupSVD (1)
EGFR S784F (1)
EGFR T263P (1)
EGFR T751_I759>S (1)
EGFR T790I (1)
EGFR T790M + BRAF V600E (1)
EGFR T790M + EGFR L792F (1)
EGFR T790M + EGFR L833V + EGFR H835L (1)
EGFR T790M + EGFR L861Q (1)
EGFR T790M + EGFR S768I + EGFR L858R (1)
EGFR T790M + HER-2 mutation (1)
EGFR T790M + KRAS G12V (1)
EGFR T790M + MET mutation (1)
EGFR T790M + PARP1 mutation (1)
EGFR T790M + PIK3CA Mutation (1)
EGFR T790M + TP53 R237C (1)
EGFR T854A + EGFR T790M (1)
EGFR T858R (1)
EGFR V769A (1)
EGFR V769_770insASV (1)
EGFR V774_C775insHV (1)
EGFR V786M (1)
EGFR V802I (1)
EGFR V834L (1)
EGFR Y764_V765insHH (1)
EGFR exon 18 mutation + EGFR exon 21 mutation (1)
EGFR exon 19 deletion + ALK mutation (1)
EGFR exon 19 deletion + ATM S1455fs*36 + MYC E62K (1)
EGFR exon 19 deletion + BRAF V600E (1)
EGFR exon 19 deletion + BRCA2 mutation (1)
EGFR exon 19 deletion + EGFR G724S + EGFR T790M (1)
EGFR exon 19 deletion + EGFR T790L (1)
EGFR exon 19 deletion + TP53 exon 8 mutation (1)
EGFR exon 19 deletion + TP53 mutation (1)
EGFR exon 19 mutation + EGFR C797S + PIK3CA mutation (1)
EGFR exon 20 insertion + EGFR G719X + EGFR L858R (1)
EGFR exon 20 insertion + NRAS G13V + NF1 R69fs + NF1 S340fs (1)
EGFR exon 20 insertion + TP53 G244A + SPTA1 mutation (1)
EGFR exon 20 mutation + EGFR V774M + EGFR S768I (1)
EGFR exon 21 deletion + EGFR L858R + MET Exon 14 mutation (1)
EGFR exon 21 mutation + EGFR L858R (1)
EGFR mutation + ALK mutation (1)
EGFR mutation + BRAF G469A (1)
EGFR mutation + BRAF mutation + TP53 mutation (1)
EGFR mutation + CTBP2 rs376695472 (1)
EGFR mutation + CTBP2 rs945665113 (1)
EGFR mutation + EGFR T790M + EGFR C797S (1)
EGFR mutation + FAT3 mutation (1)
EGFR mutation + GRM8 mutation (1)
EGFR mutation + HLA-DRB5 rs1071748 (1)
EGFR mutation + HLA-DRB5 rs184278615 (1)
EGFR mutation + HLA-DRB5 rs20146916 (1)
EGFR mutation + IDH1 mutation (1)
EGFR mutation + KIR3DL1 rs199822561 (1)
EGFR mutation + KIR3DL1 rs200821495 (1)
EGFR mutation + KIR3DL1 rs72629105 (1)
EGFR mutation + KIR3DL2 rs973541788 (1)
EGFR mutation + LRP1B mutation (1)
EGFR mutation + MDM4 *32C>A (1)
EGFR mutation + MET Y1003N (1)
EGFR mutation + NOTCH1 mutation (1)
EGFR mutation + RB1 mutation (1)
EGFR mutation + SMAD4 mutation (1)
EGFR mutation + TP53 exon 6 mutation (1)
EGFR mutation + TP53 exon 7 mutation (1)
EGFR mutation + UBXN11 mutation (1)
EGFR mutation + ZNF217 mutation (1)
EGFR mutation+ IDH1 R132H (1)
EGFR rearrangement (1)
EGFR wild-type + ALK wild-type + ROS1 wild-type (1)
EGFR wild-type + ALK wild-type + STK11 mutation (1)
EGFR wild-type + MET wild-type (1)
EGFR-SEPTIN14 rearrangement (1)
EGFR G729A + EGFR L858R (1)
EGFR T790M + TP53 mutation (1)
IDH1 R132C + EGFR L861Q (1)
IDH2 R140W + EGFR L858R (1)
KRAS codon 12 mutation + KRAS codon 13 mutation + EGFR mutation (1)
MTOR L1433S + EGFR L858R + EGFR T790M (1)
EGFR A839V (0)
EGFR E709A (0)
EGFR E709F (0)
EGFR G779C (0)
EGFR G873E (0)
EGFR H773L (0)
EGFR K754E (0)
EGFR L747_S752del (0)
EGFR L747_T750del (0)
EGFR L858R + EGFR G779S (0)
EGFR L858R + RBM10 Q255 (0)
EGFR R776C (0)
EGFR S765I (0)
EGFR T785A + EGFR L861Q + EGFR H297_E298 (0)
EGFR V774M (0)
EGFR mutation + APC mutation (0)
EGFR rs4947492 (0)
MET exon 14 skipping mutation + EGFR G709T (0)
EGFR mutation (196)
EGFR L858R (90)
EGFR exon 20 insertion (50)
EGFR wild-type (41)
EGFR L861Q (23)
EGFR C797S (22)
EGFR exon 21 mutation (20)
EGFR L858R + EGFR T790M (16)
EGFR exon 19 mutation (14)
EGFR A763_Y764insFQEA (13)
EGFR G719X (13)
EGFR S768I (12)
EGFR mutation + TP53 mutation (11)
EGFR C797S + EGFR T790M + EGFR L858R (9)
EGFR C797S + EGFR T790M + EGFR exon 19 deletion (9)
EGFR E746_A750del (8)
EGFR exon 20 mutation (8)
EGFRvIII mutation (8)
EGFR G719A (7)
EGFR G719S (7)
EGFR L747P (7)
EGFR exon 18 mutation (7)
EGFR T790M + EGFR C797S (6)
EGFR exon 19 deletion + EGFR L861Q (6)
EGFR mutation + BRAF V600E (6)
EGFR wild-type + ALK wild-type (6)
EGFR G719X + EGFR S768I (5)
EGFR K745_E746insIPVAIK (5)
EGFR G719C (4)
EGFR L861Q + EGFR G719X (4)
EGFR S492R (4)
EGFR mutation + KRAS mutation (4)
EGFR mutation + PIK3CA mutation (4)
EGFR D770 delinsGY (3)
EGFR D770_N771insSVD (3)
EGFR E709K (3)
EGFR E709_T710delinsD (3)
EGFR E746_S752delinsV (3)
EGFR G724S (3)
EGFR H773_V774insH (3)
EGFR L718Q (3)
EGFR L833V + EGFR H835L (3)
EGFR L858R + EGFR M766Q (3)
EGFR R521K (3)
EGFR T790M negative (3)
EGFR T854A (3)
EGFR exon 18-25 duplication (3)
EGFR exon 19 deletion + EGFR C797S (3)
EGFR exon 19 deletion + EGFR T790M + EGFR C797S (3)
EGFR mutation + CREBBP mutation (3)
HER-2 V777L + EGFR L858R (3)
EGFR A767_V769dup (2)
EGFR D761Y (2)
EGFR D770_N771insGT (2)
EGFR E114K (2)
EGFR G465R (2)
EGFR G63R (2)
EGFR G719A + EGFR G779C (2)
EGFR G719C + EGFR S768I (2)
EGFR G719S + EGFR L861Q (2)
EGFR G874S (2)
EGFR H1975 (2)
EGFR K708R (2)
EGFR L747-S752 del (2)
EGFR L747_A750delinsP (2)
EGFR L833F + EGFR L861Q (2)
EGFR L858R + EGFR A871G (2)
EGFR L858R + EGFR L718Q (2)
EGFR L858R + RBM10 Y36* (2)
EGFR L858R + TP53 mutation (2)
EGFR L860R (2)
EGFR L861R (2)
EGFR N771delinsKG (2)
EGFR P596L (2)
EGFR R165Q (2)
EGFR R222C (2)
EGFR S645C + EGFR L858R (2)
EGFR T790M + KRAS mutation (2)
EGFR T790M + PIK3CA H1047R (2)
EGFR V802I + KRAS mutation (2)
EGFR exon 19 duplication (2)
EGFR exon 19 insertion (2)
EGFR exon 20 insertion + EGFR T790M (2)
EGFR mutation + ATM mutation (2)
EGFR mutation + BRAF V600 (2)
EGFR mutation + CDKN2A mutation (2)
EGFR mutation + EGFR T790M (2)
EGFR mutation + MET mutation (2)
EGFR mutation + NRAS Q61K (2)
EGFR mutation + PTEN mutation (2)
EGFR mutation + TP53 mutation + ARID1A mutation (2)
EGFR mutation + TP53 mutation + BRCA1 mutation (2)
EGFR mutation + TP53 mutation + NF1 mutation (2)
EGFR mutation + TP53 mutation + PTEN mutation (2)
EGFR mutation + TP53 mutation + RB1 mutation (2)
EGFR T790L (2)
EGFR delE709_T710insD (2)
KRAS mutation + EGFR wild-type (2)
MET exon 14 mutation + EGFR exon 20 insertion (2)
ALK L1152R + EGFR mutation (1)
ALK rearrangement + ALK T1151M + ALK L1198F + EGFR A839V (1)
ALK rearrangement + EGFR D761N + KRAS V14I (1)
ALK rearrangement + TP53 R175H + EGFR A839V + PI3KCA mutation (1)
BRAF mutation + EGFR mutation (1)
CDK4 mutation + EGFR mutation (1)
DDR + EGFR mutation (1)
EGFR 181946 C>T (1)
EGFR A289V (1)
EGFR A750P (1)
EGFR A763V (1)
EGFR A767_V769dupASV (1)
EGFR A767dupASV (1)
EGFR A859T (1)
EGFR C796S (1)
EGFR C796S + EGFR V802I (1)
EGFR C797S + EGFR C796S (1)
EGFR C797S + EGFR exon 20 insertion (1)
EGFR D770_N771insGL (1)
EGFR D770_N771insGT + EGFR V774_C775insHV (1)
EGFR E690K (1)
EGFR E709A + EGFR G719C (1)
EGFR E709G (1)
EGFR E709Q (1)
EGFR E746 (1)
EGFR E746G (1)
EGFR E746_T751delinsl (1)
EGFR E758D (1)
EGFR E884K (1)
EGFR G2607A (1)
EGFR G709T (1)
EGFR G719A + EGFR I706T (1)
EGFR G719A + EGFR L833V (1)
EGFR G719A + EGFR R776C (1)
EGFR G719A + EGFR S768I (1)
EGFR G719A + EGFR T790M (1)
EGFR G719C + EGFR E709V (1)
EGFR G719D (1)
EGFR G719S + EGFR S768I (1)
EGFR G719X + EGFR E709F (1)
EGFR G719X + EGFR L861Q + EGFR S768I (1)
EGFR G719X + TP53 mutation (1)
EGFR G724S + EGFR R776H (1)
EGFR G735R (1)
EGFR G796S (1)
EGFR G836S (1)
EGFR H773L + EGFR V774M (1)
EGFR H773_V774insNPH (1)
EGFR H773delinsNPY (1)
EGFR H773delinsYNPY (1)
EGFR H835L (1)
EGFR I744_K745insKIPVAI (1)
EGFR K467T (1)
EGFR K757R (1)
EGFR L718V + TP53 V727M + EGFR L858R (1)
EGFR L746_T70delinsS (1)
EGFR L746_T750del (1)
EGFR L747S (1)
EGFR L747_A750>P (1)
EGFR L747_P753delinsS (1)
EGFR L747_T751delinsP (1)
EGFR L747_T751delinsS (1)
EGFR L747_T753delinsS (1)
EGFR L833V (1)
EGFR L8585R + EGFR T790M + RBM10 G840fs*7 (1)
EGFR L858R + ALK R1275Q (1)
EGFR L858R + ALK rearrangement (1)
EGFR L858R + EGFR C797S (1)
EGFR L858R + EGFR D761Y (1)
EGFR L858R + EGFR E709G (1)
EGFR L858R + EGFR E709X (1)
EGFR L858R + EGFR E709X + CTNNB1 mutation (1)
EGFR L858R + EGFR E884K (1)
EGFR L858R + EGFR L747V (1)
EGFR L858R + EGFR R776H (1)
EGFR L858R + EGFR S765I (1)
EGFR L858R + EGFR S768I (1)
EGFR L858R + EGFR T854A (1)
EGFR L858R + EGFR V843I (1)
EGFR L858R + EGFR exon 21 deletion (1)
EGFR L858R + FGF3 mutation (1)
EGFR L858R + IDH1 R132C (1)
EGFR L858R + PIK3CA H1047R + PIK3CA E545K (1)
EGFR L858R + RBM10 2167-1 G>T (1)
EGFR L858R + RBM10 Q255* (1)
EGFR L858R + RBM10 Q595* (1)
EGFR L858R + TP53 R273C + HER-2 S442L (1)
EGFR L858R + TP53 wild-type (1)
EGFR L861P (1)
EGFR L861Q + EGFR exon 20 insertion (1)
EGFR L861Q + TP53 mutation (1)
EGFR L861Q + TP53 mutation + RB1 mutation (1)
EGFR L861X (1)
EGFR M277E (1)
EGFR M766Q (1)
EGFR M766_A767insASV (1)
EGFR N771_P772insH (1)
EGFR N771_P772insVal (1)
EGFR P546S (1)
EGFR P753S (1)
EGFR P772_H773insYNP (1)
EGFR P772_H773insYNP + EGFR H773Y (1)
EGFR P772_V774insPHV (1)
EGFR Q787Q (1)
EGFR R1052K (1)
EGFR R451C (1)
EGFR R776C + EGFR L861Q (1)
EGFR R776H (1)
EGFR R776H + EGFR C797S (1)
EGFR R776H + EGFR L861Q (1)
EGFR S464L (1)
EGFR S720I (1)
EGFR S752_I759del (1)
EGFR S768I + TP53 mutation (1)
EGFR S768_D770dup (1)
EGFR S768_D770dupSVD (1)
EGFR S768dupSVD (1)
EGFR S784F (1)
EGFR T263P (1)
EGFR T751_I759>S (1)
EGFR T790I (1)
EGFR T790M + BRAF V600E (1)
EGFR T790M + EGFR L792F (1)
EGFR T790M + EGFR L833V + EGFR H835L (1)
EGFR T790M + EGFR L861Q (1)
EGFR T790M + EGFR S768I + EGFR L858R (1)
EGFR T790M + HER-2 mutation (1)
EGFR T790M + KRAS G12V (1)
EGFR T790M + MET mutation (1)
EGFR T790M + PARP1 mutation (1)
EGFR T790M + PIK3CA Mutation (1)
EGFR T790M + TP53 R237C (1)
EGFR T854A + EGFR T790M (1)
EGFR T858R (1)
EGFR V769A (1)
EGFR V769_770insASV (1)
EGFR V774_C775insHV (1)
EGFR V786M (1)
EGFR V802I (1)
EGFR V834L (1)
EGFR Y764_V765insHH (1)
EGFR exon 18 mutation + EGFR exon 21 mutation (1)
EGFR exon 19 deletion + ALK mutation (1)
EGFR exon 19 deletion + ATM S1455fs*36 + MYC E62K (1)
EGFR exon 19 deletion + BRAF V600E (1)
EGFR exon 19 deletion + BRCA2 mutation (1)
EGFR exon 19 deletion + EGFR G724S + EGFR T790M (1)
EGFR exon 19 deletion + EGFR T790L (1)
EGFR exon 19 deletion + TP53 exon 8 mutation (1)
EGFR exon 19 deletion + TP53 mutation (1)
EGFR exon 19 mutation + EGFR C797S + PIK3CA mutation (1)
EGFR exon 20 insertion + EGFR G719X + EGFR L858R (1)
EGFR exon 20 insertion + NRAS G13V + NF1 R69fs + NF1 S340fs (1)
EGFR exon 20 insertion + TP53 G244A + SPTA1 mutation (1)
EGFR exon 20 mutation + EGFR V774M + EGFR S768I (1)
EGFR exon 21 deletion + EGFR L858R + MET Exon 14 mutation (1)
EGFR exon 21 mutation + EGFR L858R (1)
EGFR mutation + ALK mutation (1)
EGFR mutation + BRAF G469A (1)
EGFR mutation + BRAF mutation + TP53 mutation (1)
EGFR mutation + CTBP2 rs376695472 (1)
EGFR mutation + CTBP2 rs945665113 (1)
EGFR mutation + EGFR T790M + EGFR C797S (1)
EGFR mutation + FAT3 mutation (1)
EGFR mutation + GRM8 mutation (1)
EGFR mutation + HLA-DRB5 rs1071748 (1)
EGFR mutation + HLA-DRB5 rs184278615 (1)
EGFR mutation + HLA-DRB5 rs20146916 (1)
EGFR mutation + IDH1 mutation (1)
EGFR mutation + KIR3DL1 rs199822561 (1)
EGFR mutation + KIR3DL1 rs200821495 (1)
EGFR mutation + KIR3DL1 rs72629105 (1)
EGFR mutation + KIR3DL2 rs973541788 (1)
EGFR mutation + LRP1B mutation (1)
EGFR mutation + MDM4 *32C>A (1)
EGFR mutation + MET Y1003N (1)
EGFR mutation + NOTCH1 mutation (1)
EGFR mutation + RB1 mutation (1)
EGFR mutation + SMAD4 mutation (1)
EGFR mutation + TP53 exon 6 mutation (1)
EGFR mutation + TP53 exon 7 mutation (1)
EGFR mutation + UBXN11 mutation (1)
EGFR mutation + ZNF217 mutation (1)
EGFR mutation+ IDH1 R132H (1)
EGFR rearrangement (1)
EGFR wild-type + ALK wild-type + ROS1 wild-type (1)
EGFR wild-type + ALK wild-type + STK11 mutation (1)
EGFR wild-type + MET wild-type (1)
EGFR-SEPTIN14 rearrangement (1)
EGFR G729A + EGFR L858R (1)
EGFR T790M + TP53 mutation (1)
IDH1 R132C + EGFR L861Q (1)
IDH2 R140W + EGFR L858R (1)
KRAS codon 12 mutation + KRAS codon 13 mutation + EGFR mutation (1)
MTOR L1433S + EGFR L858R + EGFR T790M (1)
EGFR A839V (0)
EGFR E709A (0)
EGFR E709F (0)
EGFR G779C (0)
EGFR G873E (0)
EGFR H773L (0)
EGFR K754E (0)
EGFR L747_S752del (0)
EGFR L747_T750del (0)
EGFR L858R + EGFR G779S (0)
EGFR L858R + RBM10 Q255 (0)
EGFR R776C (0)
EGFR S765I (0)
EGFR T785A + EGFR L861Q + EGFR H297_E298 (0)
EGFR V774M (0)
EGFR mutation + APC mutation (0)
EGFR rs4947492 (0)
MET exon 14 skipping mutation + EGFR G709T (0)
›
Related tests:
FoundationOne® CDx (110)
Guardant360® CDx (54)
cobas® EGFR Mutation Test v2 (13)
Target Selector™ EGFR Mutation Assay
therascreen® EGFR Plus RGQ PCR Kit
FoundationOne® CDx (110)
Guardant360® CDx (54)
cobas® EGFR Mutation Test v2 (13)
Target Selector™ EGFR Mutation Assay
therascreen® EGFR Plus RGQ PCR Kit
Associations
(64)
News
Trials
Search handles
@ADesaiMD
@APassaroMD
@AdnanNagrial
@AndresFCardonaZ
@CharuAggarwalMD
@ChristianRolfo
@DrCraigGedye
@DrJNaidoo
@DrSteveMartin
@GlopesMd
@HHorinouchi
@Jbauml
@Latinamd
@LeciaSequist
@MARIANOPROVENCI
@RajVaddepally
@StephenVLiu
@Tony_Calles
@VamsiVelcheti
@dipeshuprety4
@dplanchard
@dr_yakupergun
@jsoriamd
Search handles
@ADesaiMD
@APassaroMD
@AdnanNagrial
@AndresFCardonaZ
@CharuAggarwalMD
@ChristianRolfo
@DrCraigGedye
@DrJNaidoo
@DrSteveMartin
@GlopesMd
@HHorinouchi
@Jbauml
@Latinamd
@LeciaSequist
@MARIANOPROVENCI
@RajVaddepally
@StephenVLiu
@Tony_Calles
@VamsiVelcheti
@dipeshuprety4
@dplanchard
@dr_yakupergun
@jsoriamd
Filter by
Latest
11ms
#ASCO23 #LCSM 📢 Safety and efficacy of YK-029A, a new EGFR TKI, in advanced NSCLC with ex20ins, T790M or rare mutations 👩🔬🧪. ➡️ Phase 1 trial, 108 patients 🧑🤝🧑. ➡️ Most common TRAEs: diarrhea (46.3%), anemia (38.0%), and rash (32.4%) 🌡️. ➡️ For the EGFR ex20ins cohort, objective… https://t.co/gm2d0dNZY0 (@ADesaiMD)
11 months ago
Clinical • EGFR exon 20 • Metastases
|
EGFR T790M
12ms
Congrats to @MGHBreastOnc on this paper showing how a panel of resistance alterations complement ESR1 to inform outcomes to CDK4/6i in MBC! Like T790M in NSCLC, ESR1 is going to just be the tip of the resistance iceberg... https://t.co/HvVp0w8Bjz (@geoff_oxnard)
12 months ago
ER (Estrogen receptor) • CDK4 (Cyclin-dependent kinase 4)
|
EGFR T790M
1year
Osimertinib in patients experienced progression after 1st or 2nd gen EGFR-TKIs without T790M (WJOG12819L (KISEKI) @JSMO_official by Dr. Daisuke Hayakawa. ORR of 29.1% (95% CI,17.6-42.9) was demonstrated and met the pre-planned significance boundary. #JSMO2023 #LCSM (@HHorinouchi)
1 year ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR T790M
|
Tagrisso (osimertinib)
1year
#FeatureFriday Today on #FeatureFriday, we are featuring a tweet from Dr. Antonio Passaro [@APassaroMD] on how #Osimertinib, an #EGFR-tyrosine kinase inhibitor, potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance mutations in advanced NSCLC. (@4baseCare)
1 year ago
Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M
|
Tagrisso (osimertinib)
1year
🩸🧬 Analysis of acquired resistance to osimertinib in EGFR-mutated advanced NSCLC pts from the AURA3 trial: 50% undetectable plasma EGFR T790M, 19% have >1 resistance-mechanism: MET amplification (14/78, 18%) and EGFR C797X mutation (14/78, 18%). #LCSM https://t.co/r7V1qLfr4C (@Tony_Calles)
1 year ago
Clinical • Metastases
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • MET amplification • EGFR T790M
|
Tagrisso (osimertinib)
1year
Phase II EORTC Lung Cancer Group 1613 APPLE trial @Annals_Oncology. Pts with #EGFR mutant NSCLC randomized to osimertinib until PD, gefitinib until PD, or gefitinib until either T790M+ by ctDNA or PD. ctDNA led to earlier switch to osimertinib in 17%. https://t.co/TwKmrtswkC (@StephenVLiu)
1 year ago
Clinical • Circulating tumor DNA
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M
|
Tagrisso (osimertinib) • gefitinib
1year
This is analogous to the initial approval of osimertinib only for EGFR-mutant lung cancers that acquired the T790M resistance mutation, but everyone could see that it was better than other TKIs in the first line, without T790M, as the FLAURA trial eventually showed. (@UnfrznCavemanMD)
1 year ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M
|
Tagrisso (osimertinib)
over1year
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data | Future Oncology https://t.co/nSW3k53kse (@MARIANOPROVENCI)
over 1 year ago
Clinical • Real-world evidence • Real-world
|
EGFR (Epidermal growth factor receptor)
|
EGFR T790M • EGFR positive
|
Tagrisso (osimertinib)
over1year
Report of oleclumab (anti-CD73) plus osimertinib in #EGFR NSCLC @JTOonline. CD73 often overexpressed in EGFR mutant NSCLC. Explored post 1G/2G TKI, T790M negative, osi naive. At dose level 2, RR 12% with mPFS 7.4m, mOS 25m. https://t.co/we5zEtPi4r (@StephenVLiu)
over 1 year ago
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M • EGFR overexpression • CD73 overexpression • EGFR T790M negative • CD73 expression
|
Tagrisso (osimertinib) • oleclumab (MEDI9447)
over1year
Excited to share this as co-first author! 1.#EGFR detection: 💧PE-#cfDNA🧬 sensitivity > plasma (97 vs 74%) 2. PE-cfDNA🧬 detects more #T790M than cyto🔬 (high QI rate) Thanks to #KirstyLee @TonyMok9 and all colleagues! https://t.co/sXp6wRFOIw @JAMAOnc @CUHKMedicine #LCSM (@mollylisc)
over 1 year ago
EGFR (Epidermal growth factor receptor)
|
EGFR T790M
over1year
Testing Pleural and Pericardial Effusion for EGFR Variants in NSCLC @JAMAOnc 💥EGFR sensitizing variants PE-cfDNA sensitivity and specificity➡️ 97% Plasma➡️74% 💥T790M variant PE-cfDNA sensitivity ➡️87% ☑️Effusions can be analyzed with high accuracy https://t.co/bNC9clmgSb (@dr_yakupergun)
over 1 year ago
EGFR (Epidermal growth factor receptor)
|
EGFR T790M
over1year
Promising efficacy of 4th generation EGFR TKI after 3 weeks in NSCLC pt EGFR L858R, T790M, C797S mutations in progression post gefitinib, osimertinib and amivantamab...to be continued @GustaveRoussy @CICThoraciques (@dplanchard)
over 1 year ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR T790M • EGFR C797S
|
Tagrisso (osimertinib) • gefitinib • Rybrevant (amivantamab-vmjw)
over1year
Phase Ib study of telisotuzumab vedotin (teliso-V, #MET ADC) + erlotinib in cMET+ #EGFR mutant NSCLC @JCO_ASCO. RR 32% in EGFRmt and RR 53% in cMET high (H-score ≥225) with mPFS 6.8m in T790M+. Neuropathy seen in 57%. https://t.co/GFRalewa4v (@StephenVLiu)
over 1 year ago
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M
|
erlotinib • telisotuzumab vedotin (ABBV-399)
over1year
🚨🚨 Check out our latest collaboration: #UNICORN: UNcommon EGFR mutations: International Case series on efficacy of #osimertinib in 1st liNe J Bair et al. ▶️N=60, G719X L861Q & T790M ▶️ORR 61%, mOS 24.5m. compound EGFR+ did better @EGFRResisters #lcsm https://t.co/7CqrcJpiXr (@Latinamd)
over 1 year ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M • EGFR L861Q • EGFR G719X
|
Tagrisso (osimertinib)
over1year
In this multi-center, retrospective study @JTOonline for uncommon EGFR mutation (n=60), osimertinib demonstrated an ORR of 61% (44% for denovo T790M, 47% for G719X ORR & 80% for L861Q) Md PFS 9.5 mo Md DOR 17.4 mo & Md OS of 24.5 mo #LCSM @OncoAlert https://t.co/XxvURqgISg (@dipeshuprety4)
over 1 year ago
Retrospective data
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M • EGFR L861Q • EGFR G719X
|
Tagrisso (osimertinib)
over1year
Osimertinib in NSCLC w uncommon EGFR mutns @JTOonline: - 60pt retrosp study, overall ORR 66% - G719X ORR 47% mPFS 8.8m mDOR 9.1m - L861Q ORR 80% mPFS 16m mDOR 16m - de novo T790M ORR 44% mPFS 12.7m mDOR 46.2m ?⬇️ORR T790M than expected, important study https://t.co/B3kpq7AKbR (@DrJNaidoo)
over 1 year ago
EGFR (Epidermal growth factor receptor)
|
EGFR T790M • EGFR L861Q • EGFR G719X
|
Tagrisso (osimertinib)
over1year
Ph Ib TATTON (Part B) trial: Osi+Selumetinib in EGFR-mt NSCLC post EGFR-TKI: - 47pts (prior 1/2nd gen TKI=12; prior T790M-TKI=35) - ORR 67% & 22.9%; mPFS 15.0mo; 2.8mo respectively Osi+MEKi has modest 2L activity, but is the area of greatest need #LCSM https://t.co/HNJXQIscD4 (@DrJNaidoo)
over 1 year ago
EGFR (Epidermal growth factor receptor) • CD4 (CD4 Molecule)
|
EGFR T790M
|
Koselugo (selumetinib)
over1year
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study - Journal of Thoracic Oncology https://t.co/A1lp5GJDBU (@AdnanNagrial)
over 1 year ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M
|
Semena (befotertinib)
over1year
Dr. @JordiRemon presents results from the @EORTC phase II randomized APPLE trial at #ESMO22. Randomized pts with #EGFR NSCLC to 1L osimertinib vs gefitinib then osimertinib at RECIST PD (if T790M+) vs gefitinib then osimertinib when T790M+ in liquid biopsy (cobas assay). #LCSM (@StephenVLiu)
over 1 year ago
Clinical • P2 data • Liquid biopsy
|
EGFR (Epidermal growth factor receptor)
|
EGFR T790M
|
Tagrisso (osimertinib) • gefitinib
over1year
#ESMO22 #LCSM @JordiRemon presented the APPLE trial in EGFR+ NSCLC: osi treatment based on plasma T790M @EORTC Study design, here! (@APassaroMD)
over 1 year ago
EGFR (Epidermal growth factor receptor)
|
EGFR T790M
over1year
Phase IIb study of rezivertinib (BPI-7711, 3G #EGFR TKI) in T790M NSCLC @JTOonline (n=226, 2019-20). With 2y f/u, RR 64.6%, mDOR 12.5m, mPFS 12.2m, mOS 23.9m, CNS RR 69%. No interstitial lung disease. Phase III REZOR trial vs gefitinib already completed. https://t.co/yvE6JdaGBx (@StephenVLiu)
over 1 year ago
EGFR (Epidermal growth factor receptor)
|
EGFR T790M
|
gefitinib • rezivertinib (BPI-7711)
over1year
Thanks for your reply Dr. Umut. Lqd biopsy says T790M negative. PB/ TP53 positive. May be from the biopsy SCLC trans could be checked and if no, then NGS for resistance mechanism? (@siddhar99256978)
over 1 year ago
Next-generation sequencing
|
TP53 (Tumor protein P53)
|
EGFR T790M
almost2years
Another 3rd generation #EGFR TKI with results reported @JTOonline. Befotertinib (D-0316) was studied in pts with EGFR T790M NSCLC and at 75-100mg, IRC RR 68%, DCR 95%, intracranial RR 57%, mPFS 12.5m. Only 5% diarrhea and no G3+ diarrhea. #LCSM https://t.co/lICva86eNR (@StephenVLiu)
almost 2 years ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR T790M
|
Semena (befotertinib)
almost2years
Yep! I can second this. Familial cases of lung cancer have been associated with germline EGFR T790M. We also reported a case associated with myeloid sarcoma: https://t.co/EnYi0L7EYw #TumorBoardTuesday (@LaurenBzak)
almost 2 years ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR T790M
almost2years
Results from single arm phase II study of the 3rd generation #EGFR TKI limertinib (ASK120067) in EGFR T790M NSCLC now @JTOonline. Study launched in 2019 and included 301 pts. RR 69%, mPFS 11m, mOS not reached, intracranial RR 56%. G3+ diarrhea in 13%. https://t.co/fUB1aiJ8HG (@StephenVLiu)
almost 2 years ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR T790M
|
limertinib (ASK120067)
2years
Retrospective report @JTOonline: in #EGFR mutant NSCLC, co-mutations in TP53 are associated with more rapid development of resistance, even among pts with initial response to therapy and across various mechanisms of resistance (SCLC, T790M). #LCSM @IASLC https://t.co/XpjLQ9oyHB (@StephenVLiu)
2 years ago
Retrospective data
|
EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53)
|
TP53 mutation • EGFR mutation • EGFR T790M
2years
#TTLC22 P10 by Dr. @cbmeador described #EGFR NSCLC with squamous histology (at diagnosis or after transformation). Interesting that for some, squamous transformation was concurrent with genomic evolution (MET, T790M). Likely underdiagnosed - biopsy at progression is important. (@StephenVLiu)
2 years ago
EGFR (Epidermal growth factor receptor)
|
EGFR T790M
2years
Phase I results of the 3rd generation #EGFR TKI rezivertinib (BPI-7711) in EGFR T790M NSCLC @JTOonline. No DLTs and no cases of pneumonitis. In 172pts, RR 59% with mPFS 9.7m. Intracranial RR 50%. RP2D 180mg daily. #LCSM https://t.co/q1B1KxuPDv (@StephenVLiu)
2 years ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR T790M
|
rezivertinib (BPI-7711)
over2years
Phase I/II study of lazertinib (3G EGFR TKI) in #EGFR mutant with T790M @JTOonline shows RR 55%, mPFS 11m, intracranial RR 86%, good safety profile. I have equipoise with a study using lazertinib instead of osimertinib. #LCSM https://t.co/PXxltnC08M (@StephenVLiu)
over 2 years ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M
|
Tagrisso (osimertinib) • Leclaza (lazertinib)
over2years
Just out in @LungCaJournal : Sequential afatinib ➡️ osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG) by @DrSanjayPopat & colleagues @EGFRResisters @EgfrUk 👇🏼 https://t.co/ZgpoHJRZNL (@LungCaJournal)
over 2 years ago
Clinical • Observational data
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M
|
Tagrisso (osimertinib) • Gilotrif (afatinib)
over2years
ETOP-BOOSTER trial osimertinib+Bev v osi in 2L EGFR T790M+ NSCLC: No PFS/OS benefit - mPFS 15.4 v 12.3m, HR 0.96 - mOS 24 v 24.3m, HR 1.03 More tox - G3+ TRAEs 47 v 18% While 1L std of care is osi & T790M is no longer used, imp data we can learn from https://t.co/VuB0xnIoz4 (@DrJNaidoo)
over 2 years ago
EGFR (Epidermal growth factor receptor)
|
EGFR T790M
|
Tagrisso (osimertinib)
over2years
Results from the ETOP BOOSTER trial now @Annals_Oncology. Randomized phase II study of 2nd line osimertinib +/- bevacizumab in #EGFR T790M+ NSCLC. There was no difference in RR, PFS or OS and more toxicity with the combination. #LCSM @ETOP_eu @OncoAlert https://t.co/BrVk0YCVBf (@StephenVLiu)
over 2 years ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR T790M
|
Avastin (bevacizumab) • Tagrisso (osimertinib)
over2years
This ETOP study enrolled 155 pts with #EGFR NSCLC and acquired T790M after prior TKI therapy. Randomized to osimertinib 80mg/d alone or with bevacizumab 15mg/kg q3w. With 34m median f/u, no difference in PFS (primary endpoint): 15.4m osi/bev vs 12.3m osi alone (HR 0.96). (@StephenVLiu)
over 2 years ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR T790M
|
Avastin (bevacizumab) • Tagrisso (osimertinib)
over2years
Amazing discovery by Susumu Kobayashi (ala T790M fame), Koichi Goto and Co💪🙏 👀we can add the 10th actionable marker to our NSCLC magic cube- w available tx - lorla right away! Happy Thxgiving #lcsm! The CLIP1–LTK fusion is an oncogenic driver in NSCLC https://t.co/3Vu82EBSYZ (@DrSteveMartin)
over 2 years ago
CLIP1 (CAP-Gly Domain Containing Linker Protein 1)
|
EGFR T790M
over2years
Efficacy of Aumolertinib in EGFR T790M+ NSCLC: Updated Results from the APOLLO Registrational Trial Looking forward to having a lower cost alternative to osimertinib around the world @EQRxINC (in the pic phase 3 results vs gefitinib in first line) https://t.co/T1aiqJ3AB6 (@GlopesMd)
over 2 years ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR T790M
|
Tagrisso (osimertinib) • gefitinib • Ameile (aumolertinib)
over2years
Updated data from the APOLLO study of the 3rd gen #EGFR TKI aumolertinib (HS-10296, 110mg daily) in EGFR T790M NSCLC. RR 69%, DCR 93%, mDOR 15m, mPFS 12.4m, CNS RR 61%. Seems comparable to osimertinib. Aumolertinib approved in China. Bound for US? #LCSM https://t.co/fIPHAPhuNf (@StephenVLiu)
over 2 years ago
EGFR (Epidermal growth factor receptor)
|
EGFR T790M
|
Tagrisso (osimertinib) • Ameile (aumolertinib)
over2years
Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities https://t.co/5831RtF1BX (@AndresFCardonaZ)
over 2 years ago
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M • EGFR negative • EGFR T790M negative
over2years
Results from the phase II OCEAN study now @JTOonline: CNS efficacy of osimertinib 80mg in 39 pts with #EGFR T790M NSCLC and untreated brain metastases. Brain metastasis RR 67%, RECIST RR 40% and brain metastasis related PFS of 25 months. #LCSM @OncoAlert https://t.co/jyJrEg11cJ (@StephenVLiu)
over 2 years ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR T790M
|
Tagrisso (osimertinib)
over2years
Agree, lung is the obvious exception, with T790M on cfDNA. If new BRAF-dimerization agents proceed to clinic, melanoma would be another exception. But for now, tumour rebiopsy outside clinical trials would seem to be... pointless... (@DrCraigGedye)
over 2 years ago
Clinical
|
BRAF (B-raf proto-oncogene)
|
EGFR T790M
almost3years
How to overcome resistance to #egfr whether dependent or independent @SukiPaddaMD @gotoPER #ilc2021 #lungcancer #lcsm @CedarsSinai with cochairs @drgandara @DrRoyHerbstYale @HwakeleeMD loss of T790M in 42-68% of nsclc (@donnashort)
almost 3 years ago
EGFR (Epidermal growth factor receptor)
|
EGFR T790M
almost3years
Report in #JTOCRR of afatinib + xentuzumab (IGF-ligand neutralizing monoclonal) in #EGFR mutant NSCLC post TKI (non T790M). Seemed safe but no responses noted. Targeting IGFR has been disappointing (recall Clovis CO-1686, rociletinib). @JTOonline @IASLC https://t.co/l23gUG7XMa (@StephenVLiu)
almost 3 years ago
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M
|
Gilotrif (afatinib) • Xegafri (rociletinib) • xentuzumab (BI-836845)
almost3years
Small sample size but interesting report in @JTOonline on 4 patients with de novo T790M/L858R #EGFR NSCLC with acquired resistance to osimertinib. Mechanisms of resistance identified: C797S, C797S/L798I, #MET amp and MTOR L1433S. #LCSM @IASLC @OncoAlert https://t.co/7mg1KB0n8H (@StephenVLiu)
almost 3 years ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR L858R • EGFR T790M • EGFR C797S
|
Tagrisso (osimertinib)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login